Keyphrases
Atrial Fibrillation
71%
GLORIA
47%
Vitamin K Antagonists
35%
Clinical Practice
26%
GLORIA-AF
23%
Cardiology
23%
SAMe-TT2R2 Score
23%
Comparative Safety
23%
Comparative Effectiveness
23%
Clinical Research
23%
Anticoagulants
23%
Rescue Equipment
23%
Asian Patients
23%
Emergency Cooperation
23%
Oral Anticoagulants
23%
Anticoagulant Use
23%
Propensity Score Matching
13%
Adverse Outcomes
10%
Confidence Interval
10%
New-onset Atrial Fibrillation
9%
Asian Ethnicity
6%
High Risk
6%
Low Risk
6%
Hazard Ratio
6%
International Registry
5%
Anticoagulated Patients
5%
Human Coronavirus (HCoV)
5%
Anticoagulation
5%
Medicine and Dentistry
Atrial Fibrillation
76%
Antithrombotic
71%
Vitamin K Antagonist
49%
Clinical Research
23%
Post-Hoc Analysis
23%
Cardiology
23%
Coronavirinae
23%
Severe Acute Respiratory Syndrome Coronavirus 2
23%
COVID-19
23%
Coronaviridae
11%
Antivirus Agent
11%
Injury
11%
Pandemic
11%
Emergency Medical Technician
11%
Adverse Outcome
10%
Anticoagulation
8%
Apoplexy
8%
Thromboembolism
6%
Hazard Ratio
6%
Antiplatelet Drug
5%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Antivitamin K
69%
Anticoagulant Agent
47%
Cardiovascular Disease
23%
Rivaroxaban
23%
Apixaban
23%
Clinical Research
23%
Major Adverse Cardiac Event
23%
Dabigatran
22%
Bleeding
20%
Heart Infarction
16%
Cause of Death
10%
Clinical Trial
5%
Antithrombocytic Agent
5%